Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACU-026-001-1 Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

NCT06267872
View directory record Official record
Conditions
HIV
Interventions
CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 1, 2026, 2:04 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

NCT07757802
View directory record Official record
Conditions
HIV
Interventions
DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 2:04 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

NCT05903339
View directory record Official record
Conditions
Hiv
Interventions
V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 1, 2026, 2:04 PM EDT